-
Product Insights
Likelihood of Approval and Phase Transition Success Rate Model – Suvecaltamide Hydrochloride in Absence Seizure
Empower your strategies with our Likelihood of Approval and Phase Transition Success Rate Model - Suvecaltamide Hydrochloride in Absence Seizure report and make more profitable business decisions.This report provides you with the data that allows you to track and predict the specific likelihood of approval (LOA) and phase transition success rate (PTSR) of a drug using GlobalData’s proprietary machine learning algorithms developed using over 10 years of historical data. Suvecaltamide Hydrochloride in Absence Seizure Drug Details: JZP-385 (CX-8998) is under...
-
Product Insights
NewLikelihood of Approval and Phase Transition Success Rate Model – JTE-451 in Plaque Psoriasis (Psoriasis Vulgaris)
Empower your strategies with our Likelihood of Approval and Phase Transition Success Rate Model - JTE-451 in Plaque Psoriasis (Psoriasis Vulgaris) report and make more profitable business decisions. This report provides you with the data that allows you to track and predict the specific likelihood of approval (LOA) and phase transition success rate (PTSR) of a drug using GlobalData’s proprietary machine learning algorithms developed using over 10 years of historical data. JTE-451 in Plaque Psoriasis (Psoriasis Vulgaris) Drug Details: JTE-451...
-
Product Insights
NewEpilepsy Clinical Trial Analysis by Phase, Trial Status, End Point, Sponsor Type and Region, 2024 Update
GlobalData's clinical trial report, “Epilepsy - Global Clinical Trials Review, 2024" provides an overview of Epilepsy Clinical trials scenario. This report provides top line data relating to the clinical trials on Epilepsy. Report includes an overview of trial numbers and their average enrollment in top countries conducted across the globe. The report offers coverage of disease clinical trials by region, country (G7 & E7), phase, trial status, end points status and sponsor type. Report also provides prominent drugs for in-progress...
-
Product Insights
NewLikelihood of Approval and Phase Transition Success Rate Model – Pasireotide in Hypoglycemia
Empower your strategies with our Likelihood of Approval and Phase Transition Success Rate Model - Pasireotide in Hypoglycemia report and make more profitable business decisions.This report provides you with the data that allows you to track and predict the specific likelihood of approval (LOA) and phase transition success rate (PTSR) of a drug using GlobalData’s proprietary machine learning algorithms developed using over 10 years of historical data. Pasireotide in Hypoglycemia Drug Details: Pasireotide (Signifor, Upelior) is a synthetic polypeptide analogue...
-
Product Insights
NewLikelihood of Approval and Phase Transition Success Rate Model – Vorolanib in Wet (Neovascular / Exudative) Macular Degeneration
Empower your strategies with our Likelihood of Approval and Phase Transition Success Rate Model - Vorolanib in Wet (Neovascular / Exudative) Macular Degeneration report and make more profitable business decisions.This report provides you with the data that allows you to track and predict the specific likelihood of approval (LOA) and phase transition success rate (PTSR) of a drug using GlobalData’s proprietary machine learning algorithms developed using over 10 years of historical data. Vorolanib in Wet (Neovascular / Exudative) Macular Degeneration...
-
Product Insights
Likelihood of Approval and Phase Transition Success Rate Model – Zanidatamab in Non-Small Cell Lung Cancer
Empower your strategies with our Likelihood of Approval and Phase Transition Success Rate Model - Zanidatamab in Non-Small Cell Lung Cancer report and make more profitable business decisions.This report provides you with the data that allows you to track and predict the specific likelihood of approval (LOA) and phase transition success rate (PTSR) of a drug using GlobalData’s proprietary machine learning algorithms developed using over 10 years of historical data. Zanidatamab in Non-Small Cell Lung Cancer Drug Details: Zanidatamab is...
-
Product Insights
NewLikelihood of Approval and Phase Transition Success Rate Model – Zanidatamab in Adenocarcinoma Of The Gastroesophageal Junction
Empower your strategies with our Likelihood of Approval and Phase Transition Success Rate Model - Zanidatamab in Adenocarcinoma Of The Gastroesophageal Junction report and make more profitable business decisions. This report provides you with the data that allows you to track and predict the specific likelihood of approval (LOA) and phase transition success rate (PTSR) of a drug using GlobalData’s proprietary machine learning algorithms developed using over 10 years of historical data. Zanidatamab in Adenocarcinoma Of The Gastroesophageal Junction Drug...
-
Product Insights
Likelihood of Approval and Phase Transition Success Rate Model – Nemtabrutinib in Mantle Cell Lymphoma
Empower your strategies with our Likelihood of Approval and Phase Transition Success Rate Model - Nemtabrutinib in Mantle Cell Lymphoma report and make more profitable business decisions.This report provides you with the data that allows you to track and predict the specific likelihood of approval (LOA) and phase transition success rate (PTSR) of a drug using GlobalData’s proprietary machine learning algorithms developed using over 10 years of historical data. Nemtabrutinib in Mantle Cell Lymphoma Drug Details: Nemtabrutinib (ARQ-531) is under...
-
Product Insights
NewLikelihood of Approval and Phase Transition Success Rate Model – Zanidatamab in Salivary Gland Cancer
Empower your strategies with our Likelihood of Approval and Phase Transition Success Rate Model - Zanidatamab in Salivary Gland Cancer report and make more profitable business decisions. This report provides you with the data that allows you to track and predict the specific likelihood of approval (LOA) and phase transition success rate (PTSR) of a drug using GlobalData’s proprietary machine learning algorithms developed using over 10 years of historical data. Zanidatamab in Salivary Gland Cancer Drug Details: Zanidatamab is under...